Purpose: Anemia in cancer patients can be a result of the underlying cancer or related to treatment. Erythropoiesis-stimulating agents (ESAs) are an important option for many patients with chemotherapy-induced anemia, but are immersed in controversy. This article aims to reconcile conflicting opinions and provide expert guidance for appropriate ESA use.
Methods: Teleconference, email, and a face-to-face meeting were used to assess ESA therapy "interpretive" data, which included two current meta-analyses, expert guidelines, and regulatory approved indications from Canada, Europe, and the USA.
Results: Risks and benefits are associated with both red blood cell transfusions and ESA therapy, including improvements in hemoglobin levels and quality of life. ESAs have been associated with concerns regarding survival and progression of cancer, particularly when used in patients with cancer-related anemia.
Conclusion: Although safety concerns do exist, ESA therapy can be considered for use in patients with chemotherapy-induced anemia in accordance with Health Canada labeling.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2012.12.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Erythroferrone in Anemic Rats with Chronic Kidney Disease and Chemotherapy-Induced Anemia: An Early Biomarker for Hemoglobin Response and rHuEPO Hyporesponsiveness.
ACS Pharmacol Transl Sci
January 2025
Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmacy, The Chinese University of Hong Kong, Shatin 999077, Hong Kong SAR, P. R. China.
Erythroferrone (ERFE) has emerged as a potential biomarker for the erythropoiesis response following recombinant human erythropoietin (rHuEPO) treatment. While the association between ERFE and hemoglobin (HGB) response to rHuEPO is well-established in nonanemic conditions, such correlation and ERFE kinetics in anemic states remain unclear. We employed two rat models of anemia, chronic kidney disease (CKD) anemia and chemotherapy-induced anemia (CIA), to determine ERFE kinetics and its correlation with HGB responses after rHuEPO administration.
View Article and Find Full Text PDFLet It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.
Curr Oncol
December 2024
Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of growth factors, including granulocyte colony-stimulating factors (GCSFs), erythropoietin-stimulating agents (ESAs), and thrombopoietin receptor agonists (TPO-RAs), has emerged as a promising strategy for managing CIC.
View Article and Find Full Text PDFPrevalence of Iron Deficiency Anemia in Gynecological Cancer Patients Undergoing Treatment: A Two-Institution Retrospective Study.
Cureus
November 2024
Department of Obstetrics and Gynecology, Osaka General Medical Center, Osaka, JPN.
Background: Anemia in patients with cancer negatively affects their quality of life and cancer outcomes. However, most patients with chemotherapy-induced anemia (CIA) are not appropriately evaluated or treated, and the prevalence of iron deficiency anemia (IDA) in CIA remains unclear.
Methods: We retrospectively reviewed the electronic records of patients with gynecological cancer in two tertiary hospitals, between March 2023 and July 2023, and evaluated their anemia status.
Clinical efficacy and safety evaluation of Buzhongyiqi pills on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial.
J Tradit Chin Med
December 2024
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Article Synopsis
- The study aimed to assess the effectiveness and safety of Buzhongyiqi pills (BZYQP) in enhancing the appetite of colorectal cancer patients undergoing chemotherapy.
- A randomized, single-blind trial involved 62 stage II-IV colorectal cancer patients divided into two groups, alternating between BZYQP and a placebo before and after chemotherapy cycles.
- Results showed that the group taking BZYQP had significantly better appetite scores initially, but their appetite decreased after the washout period, highlighting the treatment's impact during the early chemotherapy phases.
Will Prolyl Hydroxylase Inhibitors Supplant Erythropoiesis-Stimulating Agents and IV Iron in the Treatment of Chemotherapy-Induced Anemia?
J Clin Oncol
January 2025
Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!